Laxmi Organic Industries (LXCHEM) Q1 24/25 earnings summary

Executive summary

• Strategic focus on cost and technology leadership, aiming for a top 5 global position in all active segments, with strong customer partnerships and diversified end-market exposure.

• Ambition to double revenues and triple EBITDA by FY2028, targeting a 20% ROCE.

• Achieved sequentially comparable and year-over-year growth in Q1 FY25, excluding one-off effects from Q4 FY24 and despite a scheduled plant turnaround in Essentials.

• Operational excellence and improved product mix in Specialties contributed positively.

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2024, were approved and reviewed with an unmodified opinion from statutory auditors.

Financial highlights

• Standalone Q1 FY25 revenue at INR 7,296 million, up 4% year-on-year; standalone net profit at INR 463.11 million, up from INR 379.42 million in Q1 FY24.

• Standalone EBITDA at INR 941 million, up 15% year-on-year; PBT at INR 702.84 million, up from INR 550.44 million in Q1 FY24.

• Consolidated Q1 FY25 revenue at INR 7,301 million, down 0.4% year-on-year; consolidated net profit at INR 343.51 million, down from INR 383.29 million in Q1 FY24.

• Gross margin for Q1 FY25 was 36.6% (consolidated); standalone EBITDA margin at 12.9%, consolidated EBITDA margin at 11.4%.

• Cash flow from operations at approximately INR 80 crore.

Outlook and guidance

• CapEx plan of INR 11,000 million from FY2024 to FY2028 to double revenues and triple EBITDA, with a targeted ROCE of 20%.

• Revenue from Dahej facility expected to start in FY2026, with peak contribution by FY2028.

• Specialties segment to maintain over 20% revenue from new products; Fluoro assets expected to contribute from FY25.

• Conservative margin assumptions for essentials; new product pipeline in specialties seen as upside.